Role of the central cholinergic system in the therapeutics of schizophrenia.
AbstractThe therapeutic agents currently used to treat schizophrenia effectively improve psychotic symptoms; however, they are limited by adverse effects and poor efficacy when negative symptoms of the illness and cognitive dysfunction are considered. While optimal pharmacotherapy would directly target the neuropathology of schizophrenia neither the underlying neurobiological substrates of the behavioral symptoms nor the cognitive deficits have been clearly established. Abnormalities in the neurotransmitters dopamine, serotonin, glutamate, and GABA are commonly implicated in schizophrenia; however, it is not uncommon for alterations in the brain cholinergic system (e.g., choline acetyltransferase, nicotinic and muscarinic acetylcholine receptors) to also be reported. Further, there is now considerable evidence in the animal literature to suggest that both first and second generation antipsychotics (when administered chronically) can alter the levels of several cholinergic markers in the brain as well as impair memory-related task performance. Given the well-established importance of central cholinergic neurons to information processing and cognition, it is important that cholinergic function in schizophrenia be further elucidated and that the mechanisms of the chronic effects of antipsychotic drugs on this important neurotransmitter system be identified. A better understanding of these mechanisms would be expected to facilitate optimal treatment strategies for schizophrenia as well as the identification of novel therapeutic targets. In this review, the following topics are discussed: 1) the central cholinergic system in schizophrenia 2) effects of antipsychotic drugs on central cholinergic neurons 3) important neurotrophins in schizophrenia, especially those that support central cholinergic neurons; 4) novel strategies to optimize the therapeutics of schizophrenia via the use of cholinergic compounds as primary (i.e., antipsychotic) treatments as well as adjunctive, pro-cognitive agents.
CitationCurr Neuropharmacol. 2008 Sep; 6(3):286-292
- Time-dependent cognitive deficits associated with first and second generation antipsychotics: cholinergic dysregulation as a potential mechanism.
- Authors: Terry AV Jr, Mahadik SP
- Issue date: 2007 Mar
- Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling.
- Authors: Foster DJ, Jones CK, Conn PJ
- Issue date: 2012 Dec
- [Cholinergic hypothesis in psychosis following traumatic brain injury and cholinergic hypothesis in schizophrenia: a link?].
- Authors: Bennouna M, Greene VB, Defranoux L
- Issue date: 2007 Sep
- On the trail of a cognitive enhancer for the treatment of schizophrenia.
- Authors: Stip E, Chouinard S, Boulay LJ
- Issue date: 2005 Feb
- Protracted effects of chronic oral haloperidol and risperidone on nerve growth factor, cholinergic neurons, and spatial reference learning in rats.
- Authors: Terry AV Jr, Gearhart DA, Warner S, Hohnadel EJ, Middlemore ML, Zhang G, Bartlett MG, Mahadik SP
- Issue date: 2007 Dec 5